Cargando…

A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings

Ramucirumab-induced renal dysfunction is rarely reported. The pathology of ramucirumab-associated nephropathy in past reports primarily shows thrombotic microangiopathy (TMA) lesions but podocytopathy is not yet known. We report a case of kidney injury induced by ramucirumab in a 71-year-old man wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Yuta, Kumagai, Jiro, Nagahama, Kiyotaka, Fujisawa, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929848/
https://www.ncbi.nlm.nih.gov/pubmed/33653851
http://dx.doi.org/10.1136/bcr-2020-239603
_version_ 1783659993654886400
author Nakano, Yuta
Kumagai, Jiro
Nagahama, Kiyotaka
Fujisawa, Hajime
author_facet Nakano, Yuta
Kumagai, Jiro
Nagahama, Kiyotaka
Fujisawa, Hajime
author_sort Nakano, Yuta
collection PubMed
description Ramucirumab-induced renal dysfunction is rarely reported. The pathology of ramucirumab-associated nephropathy in past reports primarily shows thrombotic microangiopathy (TMA) lesions but podocytopathy is not yet known. We report a case of kidney injury induced by ramucirumab in a 71-year-old man with cecal cancer. He was referred to our department for increasing serum creatinine (Cr) levels from 1.08 mg/dL to 2.56 mg/dL after changing anticancer drugs from bevacizumab to ramucirumab. He showed nephrotic-range proteinuria (12.1 g/gCr). A renal biopsy revealed endothelial cell injuries, such as TMA and podocytopathy with epithelial cell hyperplasia, which looked like a crescent. After discontinuing ramucirumab, his renal function and proteinuria improved, as seen by his Cr levels and proteinuria which decreased to 1.74 mg/dL and 1.21 g/gCr, respectively, in 3 months. Unlike previous reports, we found that ramucirumab caused podocyte injuries.
format Online
Article
Text
id pubmed-7929848
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-79298482021-03-19 A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings Nakano, Yuta Kumagai, Jiro Nagahama, Kiyotaka Fujisawa, Hajime BMJ Case Rep Case Report Ramucirumab-induced renal dysfunction is rarely reported. The pathology of ramucirumab-associated nephropathy in past reports primarily shows thrombotic microangiopathy (TMA) lesions but podocytopathy is not yet known. We report a case of kidney injury induced by ramucirumab in a 71-year-old man with cecal cancer. He was referred to our department for increasing serum creatinine (Cr) levels from 1.08 mg/dL to 2.56 mg/dL after changing anticancer drugs from bevacizumab to ramucirumab. He showed nephrotic-range proteinuria (12.1 g/gCr). A renal biopsy revealed endothelial cell injuries, such as TMA and podocytopathy with epithelial cell hyperplasia, which looked like a crescent. After discontinuing ramucirumab, his renal function and proteinuria improved, as seen by his Cr levels and proteinuria which decreased to 1.74 mg/dL and 1.21 g/gCr, respectively, in 3 months. Unlike previous reports, we found that ramucirumab caused podocyte injuries. BMJ Publishing Group 2021-03-02 /pmc/articles/PMC7929848/ /pubmed/33653851 http://dx.doi.org/10.1136/bcr-2020-239603 Text en © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Case Report
Nakano, Yuta
Kumagai, Jiro
Nagahama, Kiyotaka
Fujisawa, Hajime
A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings
title A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings
title_full A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings
title_fullStr A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings
title_full_unstemmed A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings
title_short A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings
title_sort case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929848/
https://www.ncbi.nlm.nih.gov/pubmed/33653851
http://dx.doi.org/10.1136/bcr-2020-239603
work_keys_str_mv AT nakanoyuta acaseoframucirumabinducedrenalfailurewithnephroticrangeproteinuriaanditspathologicalfindings
AT kumagaijiro acaseoframucirumabinducedrenalfailurewithnephroticrangeproteinuriaanditspathologicalfindings
AT nagahamakiyotaka acaseoframucirumabinducedrenalfailurewithnephroticrangeproteinuriaanditspathologicalfindings
AT fujisawahajime acaseoframucirumabinducedrenalfailurewithnephroticrangeproteinuriaanditspathologicalfindings
AT nakanoyuta caseoframucirumabinducedrenalfailurewithnephroticrangeproteinuriaanditspathologicalfindings
AT kumagaijiro caseoframucirumabinducedrenalfailurewithnephroticrangeproteinuriaanditspathologicalfindings
AT nagahamakiyotaka caseoframucirumabinducedrenalfailurewithnephroticrangeproteinuriaanditspathologicalfindings
AT fujisawahajime caseoframucirumabinducedrenalfailurewithnephroticrangeproteinuriaanditspathologicalfindings